RecruitingNCT05366153
Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer
Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer (REDEEM-CAD)
Sponsor
Baker Heart and Diabetes Institute
Enrollment
748 participants
Start Date
Oct 18, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago.
Eligibility
Min Age: 40 YearsMax Age: 70 Years
Inclusion Criteria1
- A history of cancer >5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).
Exclusion Criteria6
- Unable to provide written informed consent to participate in this study
- Known coronary artery disease at recruitment
- History of previous coronary artery disease
- Inability to acquire interpretable CT images
- Contraindications/Intolerance to or already taking statin therapy
- Oncologic (or other) life expectancy <12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTCoronary CT
Screening/Management Plan
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05366153
Related Trials
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
NCT0677963019 locations
Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions
NCT067368998 locations
Hybrid Group Singing
NCT073551921 location
Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease
NCT067102101 location
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT0542737043 locations